Management and outcomes of malignant paragangliomas and phaeochromocytomas Abstract #124

Introduction: Chromaffin-cell tumors include phaeochromocytomas and paragangliomas, represent a rare group of neuroendocrine tumors and are located in adrenal medulla or extra-adrenal sites, respectively. Ten percent of phaeochromocytomas and 15-35% of paragangliomas are malignant.
Aim(s): To review the management and outcome of a series of malignant paragangliomas/phaeochromocytomas diagnosed and treated in our unit.
Materials and methods: Twenty-three patients (11 patients with paragangliomas and 12 patients with phaeochromocytomas) were included. Tumor histology was assessed according to ENETS Guidelines. Response to therapy was assessed clinically and radiologically according to the RECIST criteria.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: DR Christos Toumpanakis

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1801 Peptide Receptor Radionuclide Therapy (PRRT) with a Somatostatin Receptor (SSTR) Antagonist in Patients with SSTR-Positive, Progressive Neuroendocrine Tumours (NETs): A Phase I/II Open-Label Trial to Evaluate the Safety and Preliminary Efficacy of 177Lu-O
Introduction: PRRT with radiolabelled SSTR agonists is highly effective and has become an integral part of NET treatment. Tumour uptake and tumour-to-tissue dose ratios may be higher with radiolabelled SSTR antagonists than agonists. DOTA-JR11 (OPS201) is a very promising next-generation SSTR2-selective antagonist.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Guillaume Nicolas
Keywords: PRRT, 177Lu, OPS201
#1904 Treatment of Paragangliomas with Lutetium-177-Octreotate Based Peptide Receptor Radionuclide Therapy
Introduction: Paragangliomas (PGL) are a heterogeneous group of rare tumours that can express high numbers of somatostatin receptors on their cell surface and can be targeted with peptide receptor radionuclide therapy (PRRT) using the radiolabelled somatostatin analogue [lutetium-177-DOTA-Tyr3-]octreotate (177Lu-octreotate).
Conference: 14th Annual ENETS conference 2017 (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: Daan Smit Duijzentkunst
Keywords: PRRT, paragangliomas
#2967 Longitudinal Changes in Plasma 5-Hydroxyindoleacetic Acid (5-HIAA) and Other Biomarkers during Treatment of Functional Midgut Neuroendocrine Tumours (NETs) with Lanreotide Autogel: CALM NET Study Results
Introduction: CALM-NET (EudraCT 2013-002194-22; NCT02075606) evaluated pre-treatment circulating tumour cell levels in patients with NETs as a predictor of response to lanreotide autogel (LAN).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: Dr Tahir Shah
Authors: Shah T, Caplin M, Khan M, Houchard A, ...
#941 Comparison of Radiolableled Somatostatin Analogues and (131) I-MIBG Treatment for the Management of Patients with Metastatic/Progressive Phaeochromocytomas and Paragangliomas
Introduction: Radionuclide therapy has been used to treat patients with progressive/metastatic paragangliomas (PGGs) and pheochromocytomas (PCCs). To date, there is no study comparing (131)I-MIBG and peptide receptor radionuclide treatment (PRRT) in those patients.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Christos Toumpanakis
#1777 Tumour Size Is Not a Reliable Criterion for Resection of Patients with Non-Secreting Pancreatic Neuroendocrine Tumours: Results of an International, Multi-Centre, Operative Cohort
Introduction: Small pancreatic neuroendocrine tumours (pNETs) present a management dilemma between surveillance and resection.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Surgical treatment
Presenting Author: Logan Mills